Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

BACKGROUND: In the evaluation of PD-L1 expression to select patients for anti-PD-1/PD-L1 treatment, uniform guidelines that account for different immunohistochemistry assays, different cell types and different cutoff values across tumor types are lacking. Data on how different scoring methods compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Hua, Ding, Qingqing, Gong, Yun, Gilcrease, Michael Z., Zhao, Min, Zhao, Jun, Sui, Dawen, Wu, Yun, Chen, Hui, Liu, Hui, Zhang, Jinxia, Resetkova, Erika, Moulder, Stacy L., Wang, Wei-Lien, Huo, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310491/
https://www.ncbi.nlm.nih.gov/pubmed/32576238
http://dx.doi.org/10.1186/s13058-020-01303-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310491/
https://www.ncbi.nlm.nih.gov/pubmed/32576238
http://dx.doi.org/10.1186/s13058-020-01303-9

Ejemplares similares